MedicalMinute: Updates on Emerging Oral Therapies for IBD

Review safety and efficacy data on new and emerging oral therapies for IBD, including S1PR modulators and JAK-STAT inhibitors.
Millie D. Long, MD, MPH, FACG, AGAF
Format: Microsoft PowerPoint (.ppt)
File Size: 2.25 MB
Released: August 24, 2021

Acknowledgements

Provided by Clinical Care Options

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Bristol-Myers Squibb

Related Content

On-demand webcast featuring an expert panel with insight on new data presented at ECCO 2022 for Crohn disease and ulcerative colitis from Clinical Care Options (CCO)

Uma Mahadevan, MD Bruce E. Sands, MD, MS Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: May 19, 2022 Expired: May 18, 2023

Clinical Care Options (CCO) presents expert commentary on new data in Crohn disease and ulcerative colitis from ECCO 2022

Bruce E. Sands, MD, MS Released: May 13, 2022

Expert slides from Clinical Care Options (CCO) on new data from ECCO 2022 17th Congress Meeting in patients with Crohn disease and ulcerative colitis

Uma Mahadevan, MD Bruce E. Sands, MD, MS Released: May 6, 2022

Expert commentary on the role of HLA-DQA1*05 in patients with IBD receiving anti-TNF therapy, from Clinical Care Options (CCO)

Marla Dubinsky, MD Bruce E. Sands, MD, MS Released: March 2, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings